Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.

Recent trials have questioned the clinical benefit of beta-blockers in post-myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). However, differences in pathophysiology and risk profile between MI with and without ST-segment elevation (STEMI and NSTEMI) may i...

Full description

Bibliographic Details
Authors: Raposeiras-Roubín, Sergio, Anguita, Manuel, Latini, Roberto, Domínguez-Rodríguez, Alberto, Barrabés, José A, Sánchez, Pedro L, Ottani, Filippo, Pocock, Stuart, Owen, Ruth, Cristobo, Pablo, Gómez-Talavera, Sandra, Staszewsky, Lidia, Escalera, Noemí, Fernández-Vázquez, Felipe, Bianco, Matteo, Prada-Delgado, Óscar, Pérez-García, Carlos Nicolás, Pelizzoni, Valentina, Navarro, Felipe, Pérez-Rivera, José-Ángel, Martín-Gorria, Gonzalo, Vetrano, Alfredo, Fuster, Valentín, Rosselló, Xavier, Ibáñez, Borja
Format: article
Publication Date:2026
Country:España
Institution:Instituto de Salud Carlos III (ISCIII)
Repository:Repisalud
Language:English
OAI Identifier:oai:dnet:repisalud__::9e3b9a705da2414a497e34c3243ade62
Online Access:https://hdl.handle.net/20.500.12105/27446
Access Level:Open access
Keyword:Acute coronary syndrome
Beta-blockers
Bloqueadores beta
Ensayo clínico aleatorizado
IAMCEST
IAMSEST
NSTEMI
Randomized controlled trial
STEMI
Síndrome coronario agudo
id ES_c1849d97b1bfa2b751f77825e44deb64
oai_identifier_str oai:dnet:repisalud__::9e3b9a705da2414a497e34c3243ade62
network_acronym_str ES
network_name_str España
repository_id_str
spelling Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.Raposeiras-Roubín, SergioAnguita, ManuelLatini, RobertoDomínguez-Rodríguez, AlbertoBarrabés, José ASánchez, Pedro LOttani, FilippoPocock, StuartOwen, RuthCristobo, PabloGómez-Talavera, SandraStaszewsky, LidiaEscalera, NoemíFernández-Vázquez, FelipeBianco, MatteoPrada-Delgado, ÓscarPérez-García, Carlos NicolásPelizzoni, ValentinaNavarro, FelipePérez-Rivera, José-ÁngelMartín-Gorria, GonzaloVetrano, AlfredoFuster, ValentínRosselló, XavierIbáñez, BorjaAcute coronary syndromeBeta-blockersBloqueadores betaEnsayo clínico aleatorizadoIAMCESTIAMSESTNSTEMIRandomized controlled trialSTEMISíndrome coronario agudoRecent trials have questioned the clinical benefit of beta-blockers in post-myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). However, differences in pathophysiology and risk profile between MI with and without ST-segment elevation (STEMI and NSTEMI) may influence the effect of beta-blockers. In this prespecified subgroup analysis of the REBOOT trial, which randomized invasively managed MI patients with LVEF > 40% to beta-blockers or control, we evaluated differences in long-term effects of the intervention between STEMI (n = 4296) and NSTEMI (n = 4142). The primary endpoint was a composite of all-cause death, reinfarction, or heart failure hospitalization over a median follow-up of 3.7 years.EDICIONES DOYMA20262026-04-2720262026-04-2320262026-04-23research articlehttp://purl.org/coar/resource_type/c_2df8fbb1Phttp://purl.org/coar/version/c_fa2ee174bc00049finfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12105/27446reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)InglésengES MICIU AEI 501100011033ES CEX2020-001041-S MICIU 10.13039open accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:dnet:repisalud__::9e3b9a705da2414a497e34c3243ade622026-06-12T12:43:37Z
dc.title.none.fl_str_mv Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
title Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
spellingShingle Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
Raposeiras-Roubín, Sergio
Acute coronary syndrome
Beta-blockers
Bloqueadores beta
Ensayo clínico aleatorizado
IAMCEST
IAMSEST
NSTEMI
Randomized controlled trial
STEMI
Síndrome coronario agudo
title_short Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
title_full Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
title_fullStr Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
title_full_unstemmed Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
title_sort Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.
dc.creator.none.fl_str_mv Raposeiras-Roubín, Sergio
Anguita, Manuel
Latini, Roberto
Domínguez-Rodríguez, Alberto
Barrabés, José A
Sánchez, Pedro L
Ottani, Filippo
Pocock, Stuart
Owen, Ruth
Cristobo, Pablo
Gómez-Talavera, Sandra
Staszewsky, Lidia
Escalera, Noemí
Fernández-Vázquez, Felipe
Bianco, Matteo
Prada-Delgado, Óscar
Pérez-García, Carlos Nicolás
Pelizzoni, Valentina
Navarro, Felipe
Pérez-Rivera, José-Ángel
Martín-Gorria, Gonzalo
Vetrano, Alfredo
Fuster, Valentín
Rosselló, Xavier
Ibáñez, Borja
author Raposeiras-Roubín, Sergio
author_facet Raposeiras-Roubín, Sergio
Anguita, Manuel
Latini, Roberto
Domínguez-Rodríguez, Alberto
Barrabés, José A
Sánchez, Pedro L
Ottani, Filippo
Pocock, Stuart
Owen, Ruth
Cristobo, Pablo
Gómez-Talavera, Sandra
Staszewsky, Lidia
Escalera, Noemí
Fernández-Vázquez, Felipe
Bianco, Matteo
Prada-Delgado, Óscar
Pérez-García, Carlos Nicolás
Pelizzoni, Valentina
Navarro, Felipe
Pérez-Rivera, José-Ángel
Martín-Gorria, Gonzalo
Vetrano, Alfredo
Fuster, Valentín
Rosselló, Xavier
Ibáñez, Borja
author_role author
author2 Anguita, Manuel
Latini, Roberto
Domínguez-Rodríguez, Alberto
Barrabés, José A
Sánchez, Pedro L
Ottani, Filippo
Pocock, Stuart
Owen, Ruth
Cristobo, Pablo
Gómez-Talavera, Sandra
Staszewsky, Lidia
Escalera, Noemí
Fernández-Vázquez, Felipe
Bianco, Matteo
Prada-Delgado, Óscar
Pérez-García, Carlos Nicolás
Pelizzoni, Valentina
Navarro, Felipe
Pérez-Rivera, José-Ángel
Martín-Gorria, Gonzalo
Vetrano, Alfredo
Fuster, Valentín
Rosselló, Xavier
Ibáñez, Borja
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Acute coronary syndrome
Beta-blockers
Bloqueadores beta
Ensayo clínico aleatorizado
IAMCEST
IAMSEST
NSTEMI
Randomized controlled trial
STEMI
Síndrome coronario agudo
topic Acute coronary syndrome
Beta-blockers
Bloqueadores beta
Ensayo clínico aleatorizado
IAMCEST
IAMSEST
NSTEMI
Randomized controlled trial
STEMI
Síndrome coronario agudo
description Recent trials have questioned the clinical benefit of beta-blockers in post-myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). However, differences in pathophysiology and risk profile between MI with and without ST-segment elevation (STEMI and NSTEMI) may influence the effect of beta-blockers. In this prespecified subgroup analysis of the REBOOT trial, which randomized invasively managed MI patients with LVEF > 40% to beta-blockers or control, we evaluated differences in long-term effects of the intervention between STEMI (n = 4296) and NSTEMI (n = 4142). The primary endpoint was a composite of all-cause death, reinfarction, or heart failure hospitalization over a median follow-up of 3.7 years.
publishDate 2026
dc.date.none.fl_str_mv 2026
2026-04-27
2026
2026-04-23
2026
2026-04-23
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
P
http://purl.org/coar/version/c_fa2ee174bc00049f
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/27446
url https://hdl.handle.net/20.500.12105/27446
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv ES MICIU AEI 501100011033
ES CEX2020-001041-S MICIU 10.13039
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv EDICIONES DOYMA
publisher.none.fl_str_mv EDICIONES DOYMA
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418566899466240
score 15,812429

Similar Items